Psychiatric Drugs Explained
- 7th Edition - April 13, 2022
- Imprint: Elsevier
- Author: David Healy
- Language: English
- Paperback ISBN:9 7 8 - 0 - 7 0 2 0 - 8 3 9 0 - 7
- eBook ISBN:9 7 8 - 0 - 7 0 2 0 - 8 3 9 1 - 4
Psychiatric Drugs Explained offers a wealth of evidence-based information on psychiatric drugs in an easy-to-use format that can be quickly referenced in the clinical setting.… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePsychiatric Drugs Explained offers a wealth of evidence-based information on psychiatric drugs in an easy-to-use format that can be quickly referenced in the clinical setting.
Written by internationally recognised author Dr David Healy, the book provides a comprehensive review of drug effects, action and side-effects. There is an emphasis on the lived experience of patients, providing the reader with a sense of what the adverse effects of drugs might feel like to those who use them.
A reader-friendly approach and clear layout, with information organised by disorder, make this popular title accessible and useful not only to nursing staff, but to all members of the multidisciplinary team.
- Quick reference guide suitable for all members of the multidisciplinary team
- Helpful boxes on user issues make potential complications easy to spot
- Distinctive, reader-friendly style helps the reader understand the benefits and impacts of psychotropic drugs
- New topics include management of dependence disorders, stimulants and drugs for children, cognitive impairment and sleep disorders
- The only book with detailed coverage of the sexual side effects of psychiatric drugs and the abusive prescribing of prescription drugs
- Cover image
- Title page
- Table of Contents
- Copyright
- Preface
- Introduction
- Consumers and Compliance
- Individual End-Points
- Pharmacopsychology
- 1. The person on treatment
- Chapter contents
- Introduction
- Christmas tree light bulb test
- Section 1: Management of the Psychoses
- 2. The antipsychotics
- Chapter contents
- Introduction
- History of the antipsychotics
- Are antipsychotics antischizophrenic?
- How antipsychotics work
- A ‘who cares’ feeling
- Antipsychotics and positive symptoms of psychosis
- Antipsychotics and negative schizophrenia
- Clozapine and second-generation antipsychotics
- Antipsychotic doses
- Flexible therapy
- For how long should treatment continue?
- Depot antipsychotics
- Antiemetics
- Antipsychotics and psychotherapy
- Significant interactions
- Special conditions
- 3. Antipsychotic side effects and their management
- Chapter contents
- Introduction
- Dopamine system effects and side effects
- Non-dopamine side effects
- Management of side effects
- References
- Section 2: Management of Depression
- 4. The antidepressants
- Chapter contents
- Introduction
- History
- Depression
- Do antidepressants work?
- What do Antidepressants do?
- Antidepressants: first choice or last resort?
- Starting antidepressants
- Stopping antidepressants
- Antidepressants and children
- 5. Side effects of antidepressants
- Chapter contents
- Introduction
- The ambiguous side effects of antidepressants
- Effects special to the MAOIs
- References
- Section 3: Management of Bipolar Disorders
- 6. Management of acute bipolar disorder
- Chapter contents
- Introduction
- Lithium for mania
- Antipsychotics for mania
- Anticonvulsants for mania
- Carbamazepine
- Sodium valproate
- Lamotrigine, gabapentin and oxcarbazepine
- Topiramate and vigabatrin
- Acetazolamide
- Electroconvulsive therapy (ECT)
- Benzodiazepines
- Do antidepressants cause mania?
- Bipolar-mania
- 7. Mood-stabilisers
- Chapter contents
- History of mood-stabilisation
- Lithium as a mood-stabiliser
- The anticonvulsant mood-stabilisers
- Carbamazepine and oxcarbazepine
- Sodium and semi-sodium valproate
- Lamotrigine
- Gabapentin and pregabalin
- Topiramate and levetiracetam
- Antipsychotics as mood-stabilisers
- Cocktail treatment
- Coda
- References
- Section 4: Psychotropic Drugs For Children
- 8. Stimulants and drugs for children
- Chapter contents
- The history of the stimulants
- The emergence of ADHD
- Stimulant treatment for ADHD
- Non-stimulant drug treatments of ADHD
- Non-drug treatments of ADHD
- Other uses of stimulants
- Psychotropic drugs and children: general principles
- The use of antidepressants for children
- The use of antipsychotics for children
- References
- Section 5: Management of Anxiety
- 9. The anxiety disorders
- Chapter contents
- Drugs used in anxiety
- Forms of anxiety
- The notion of an anxiolytic
- 10. Benzodiazepine and gabapentinoid anxiolytics
- Chapter contents
- Introduction
- Mechanism of action of the benzodiazepines
- Classes of benzodiazepines
- Clinical uses for benzodiazepines
- Benzodiazepine dependence and withdrawal
- Gabapentinoids
- 11. Serotonin and anxiolysis
- Chapter contents
- Introduction
- Serotonergic receptors and drugs
- Serotonin and anxiolysis
- 12. Beta-blockers and anxiety
- Chapter contents
- Introduction
- Performance-related anxiety
- Generalised anxiety disorder (GAD)
- Panic attacks: a puzzle?
- Tremor
- Akathisia and restlessness
- Prazosin and post-traumatic stress disorder (PTSD)
- References
- Section 6: Management of Sleep Disorders and Insomnia
- 13. Sleep disorders and insomnia
- Chapter contents
- Introduction
- The sleep disorders
- Insomnia
- 14. Non-pharmacological management of insomnia
- Chapter contents
- Caffeine
- Environmental factors
- Relaxation
- Body awareness
- Stimulus-control treatments
- Routines
- Paradoxical intention
- Forward planning
- Use of mantras and yogic breathing exercises
- Medication
- 15. Hypnotics
- Chapter contents
- Introduction
- Common hypnotics
- 16. Sedatives
- Chapter contents
- Melatonin and its analogues
- Chloral compounds
- Barbiturates and related compounds
- Chlormethiazole
- Sedative antidepressants and antipsychotics
- Antihistamines
- References
- Section 7: Management of Cognitive Impairment
- 17. Cognitive enhancement and the dementias
- Chapter contents
- Introduction
- The dementias
- 18. Cognitive enhancement and neuroprotection
- Chapter contents
- Introduction
- Second-generation cholinomimetics
- Cholinomimetics in other therapeutic areas
- Memantine (EVISTA)
- Management of multi-infarct dementia
- Management of subcortical dementias
- Neuroprotection
- Cognitive enhancement and the politics of diagnosis
- Smart drugs
- References
- Section 8: Management of Sexual Difficulties
- 19. The range of sexual difficulties
- Chapter contents
- Introduction
- Women and men
- Male potency
- Ejaculation and orgasm
- Libido
- Sexual responses in women
- Sexual orientation, objects and practices
- 20. Effects of drugs on aspects of sexual functioning
- Chapter contents
- Drug effects on sexual function: males (See Appendix 20.1)
- Ejaculatory and orgasmic effects
- Drug effects on sexual function: females (See Appendix 20.2)
- Aphrodisiacs
- Yohimbine, trazodone and cyproheptadine
- Intrapenile treatments
- Phosphodiesterase inhibitors
- Anti-aphrodisiacs
- Post-SSRI sexual dysfunction (PSSD)
- Persistent genital arousal disorder (PGAD)
- Appendix 20.1
- References
- Section 9: Management of Dependence and Withdrawal
- 21. Dependence and withdrawal
- Chapter contents
- Introduction
- Rebound symptoms
- Withdrawal syndromes
- Brain physiology
- Tolerance
- Withdrawal syndrome
- 22. Dependence and craving
- Chapter contents
- Introduction
- Craving
- Behavioural sensitisation
- Appetites
- Pharmacological management of appetites
- Psychological factors in substance abuse
- Disinhibition
- 23. Dependence and protracted withdrawal
- Chapter contents
- Historical perspective
- Antipsychotic and antidepressant dependence
- Stress syndromes
- Protracted withdrawal or legacy effects?
- References
- Section 10: Consent, Abuse And Liability
- 24. Consent
- Chapter contents
- Introduction
- Voluntary consent
- Information and comprehension
- Clinical trials and legal jeopardy
- Compliance
- Prescribing
- 25. Pharmacological abuse
- Chapter contents
- The problem
- The dynamics of abuse
- Prescription ‘rights’
- The Right not to be disabled by treatment
- References
- Section 11: The Marketing Of Tranquillity
- 26. The ethical industry
- Chapter contents
- Introduction
- The magic bullet
- The interface between ethics and markets
- Consequences
- 27. Evidence-biased care
- Chapter contents
- Access to data
- The origin of randomised trials
- The placebo effect
- Rcts and efficacy
- What's wrong with RCTs?
- Pharmagnosia
- Rcts are risky
- 28. Marketing and risk
- Chapter contents
- The marketing of depression
- The marketing of bipolar disorder
- The marketing of female sexual dysfunction
- Rating scale mongering
- Risk management
- The new marketing
- 29. From healthcare to pharmageddon
- Chapter contents
- Perceptions of progress in mental health
- Healthcare versus health products ltd
- Pharmageddon
- References
- Index
- Edition: 7
- Published: April 13, 2022
- Imprint: Elsevier
- No. of pages: 356
- Language: English
- Paperback ISBN: 9780702083907
- eBook ISBN: 9780702083914
DH
David Healy
A professor of Psychiatry in Wales, David studied medicine in Dublin, and at Cambridge University. He is a former Secretary of the British Association for Psychopharmacology, and has authored more than 200 peer-reviewed articles, 200 other pieces, and 20 books, including The Antidepressant Era and The Creation of Psychopharmacology from Harvard University Press, The Psychopharmacologists Volumes 1-3 and Let Them Eat Prozac from New York University Press, and Mania from Johns Hopkins University Press.
David’s latest book, Pharmageddon, documents the riveting and terrifying story of how pharmaceutical companies have hijacked healthcare in America and the life-threatening results.
David’s main areas of research are clinical trials in psychopharmacology, the history of psychopharmacology, and the impact of both trials and psychotropic drugs on our culture.
Affiliations and expertise
Director, North Wales Department of Psychological Medicine, College of Medicine, Cardiff University, Bangor, UK